REG - Burning Rock Biotech - Announces Resignation and Appointment of Directors

Burning Rock BiotechAnnouncement

28/06/2023 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb2220Ea&default-theme=true

RNS Number : 2220E  Burning Rock Biotech Limited  28 June 2023

Burning Rock Announces Resignation and Appointment of Directors

 

GUANGZHOU, China, June 28, 2023 -- Burning Rock Biotech Limited (NASDAQ: BNR
and LSE: BNR, the "Company" or "Burning Rock"), a company focused on the
application of next generation sequencing (NGS) technology in the field of
precision oncology, today announced the resignation of Dr. Shaokun (Shannon)
Chuai as a director from the board of directors of the Company (the "Board")
and as the Company's Chief Scientific Officer, effective June 30, 2023. Dr.
Shaokun (Shannon) Chuai will continue to serve as a senior advisor to the
Company. Dr. Zhihong (Joe) Zhang, the Company's Chief Technology Officer since
March 2016, has been appointed as a new director of the Board, effective June
30, 2023.

 

Mr. Yusheng Han, Burning Rock's founder, chairman of the Board and chief
executive officer, commented, "We would like to take this opportunity to thank
Shannon for her high-impact service to Burning Rock since 2014. Through her
long tenure at Burning Rock, Shannon has played an instrumental role in
building Burning Rock's product solutions, driving their adoption with leading
physicians at industry-leading forums, and building our science team. We wish
her the best in her new endeavors."

 

Dr. Chuai commented, "I have had an exhilarating, productive journey at
Burning Rock. I am very proud of the product portfolio that we have developed
over time with our team, spanning across comprehensive genomic profiling for
late-stage oncology patients, minimal residual disease (MRD) for early-stage
patients and multi-cancer early detection. Each product category has reached
strong maturity with their respective product leaders and is well on track in
terms of commercial adoption. I am also proud of the talent that we have
developed internally at Burning Rock. In the past seven months in my
transition from Chief Operating Officer to Chief Scientific Officer, our team
leaders have demonstrated strong leadership in driving the agenda forward and
pushing the boundary of our industry in new breakthroughs. So I think now is
the right time for me to move on, to do something new that I have never done
before, in a totally different industry outside of all my previous career
paths. I am proud of our collective achievements at Burning Rock and am highly
confident of Burning Rock's future going forward."

 

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
guard life via science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward- looking
statements can be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes," "estimates,"
"target," "confident" and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports to the SEC,
in its annual report to shareholders, in press releases and other written
materials and in oral statements made by its officers, directors or employees
to third parties. Statements that are not historical facts, including
statements about Burning Rock's beliefs and expectations, are forward-looking
statements. Such statements are based upon management's current expectations
and current market and operating conditions, and relate to events that involve
known or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock's control.
Forward-looking statements involve risks, uncertainties and other factors that
could cause actual results to differ materially from those contained in any
such statements. All information provided in this press release is as of the
date of this press release, and Burning Rock does not undertake any obligation
to update any forward-looking statement as a result of new information, future
events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFPMRTMTATMLJ